Accelerating the Fill/Finish Line to Vial SARS-CoV-2 Vaccines for Upcoming Clinical Trials

coronovirus in conversation banner

Accelerating the Fill/Finish Line to Vial SARS-CoV-2 Vaccines for Upcoming Clinical Trials

As the number of SARS-CoV-2 cases exceed 7 million and vaccine development efforts are ramped up at unprecedented speed, there are pertinent challenges faced in the preparation and execution of clinical trials, one of which is speeding up the fill/finish line to vial the vaccines. As part of the Corona360 – In Conversation series, the “Accelerating the Fill/Finish Line to Vial SARS-CoV-2 Vaccines for Upcoming Clinical Trials” live moderated discussion aims at addressing these obstacles faced by companies, which are in the clinical development phase.

Interview Details

25th June 2020, Thursday

3:30:00 (GMT +8:00)

Register Now

Add to Calendar

  • Scientists and researchers working on SARS-CoV-2 vaccine development from BIG Pharmas, vaccine manufacturers and research institutions.
  • CROs, technology / service providers and logistics partners keen on understanding how they can alleviate the challenges faced in the clinical trial phase and development chain.
  • Strategies to address SARS-CoV-2 vaccine clinical trial challenges from the get-go.
  • How CROs, technology / service providers and logistics partners may step in to fill the gaps in SARS-CoV-2 vaccine clinical trial testing demand.
  • Recommendations on how lessons learnt from this experience can be applied to other emerging infectious diseases and future pandemics.

Meet Our Silver Sponsor

Meet Our Esteemed Panelists

Kwang Kok Li, Manager, West Pharmaceutical Services, Singapore

Amgad Gamil, Senior Director, Pfizer, UAE

S K Jana, Director R&D & Manufacturing, Serum Institute of India, India

Ramesh Matur, SVP & Head R&D – Vaccines, Biological E Ltd, India

Ravi Ganapathy, Head of Vaccine Process Development, IVI, Korea

Ivana Haluskova Balter, Consultant, French Society of Immunology, France

Key Discussion Points

  • Updates from the panelists on their current stage of SARS-CoV-2 vaccine development
  • Discuss the actions required to ensure that the fill/finish capacity is available for SARS-CoV-2 vaccines
  • How to effectively scale-up the fill/finish operations with upcoming clinical trials

Market Intelligence